{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T20:39:59Z","timestamp":1771101599779,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T00:00:00Z","timestamp":1290038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s10067-010-1616-y","type":"journal-article","created":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T06:24:47Z","timestamp":1289975087000},"page":"259-262","source":"Crossref","is-referenced-by-count":42,"title":["Delays in recognition and management of giant cell arteritis: results from a retrospective audit"],"prefix":"10.1007","volume":"30","author":[{"given":"Amara N.","family":"Ezeonyeji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances A.","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,18]]},"reference":[{"key":"1616_CR1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11882-008-0052-4","volume":"8","author":"FA Borg","year":"2008","unstructured":"Borg FA, Salter VL, Dasgupta B (2008) Neuro-ophthalmic complications in giant cell arteritis. Curr Allergy Asthma Rep 8:323\u2013330","journal-title":"Curr Allergy Asthma Rep"},{"key":"1616_CR2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","volume":"79","author":"MA Gonzalez-Gay","year":"2000","unstructured":"Gonzalez-Gay MA, Garcia-Porrua C, Llorca J et al (2000) Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Med Baltim 79:283\u2013292","journal-title":"Med Baltim"},{"key":"1616_CR3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-9343(01)00770-7","volume":"111","author":"E Liozon","year":"2001","unstructured":"Liozon E, Herrmann F, Ly K et al (2001) Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111:211\u2013217","journal-title":"Am J Med"},{"key":"1616_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bmj.298.6666.75","volume":"298","author":"PA Sandercock","year":"1989","unstructured":"Sandercock PA, Warlow CP, Jones LN, Starkey IR (1989) Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. BMJ 298:75\u201380","journal-title":"BMJ"},{"key":"1616_CR5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0002-9343(79)90744-7","volume":"67","author":"BW Goodman Jr","year":"1979","unstructured":"Goodman BW Jr (1979) Temporal arteritis. Am J Med 67:839\u2013852","journal-title":"Am J Med"},{"key":"1616_CR6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/rheumatology\/36.2.251","volume":"36","author":"C Font","year":"1997","unstructured":"Font C, Cid MC, Coll-Vinent B, Lopez-Soto A, Grau JM (1997) Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 36:251\u2013254","journal-title":"Br J Rheumatol"},{"key":"1616_CR7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","volume":"112","author":"H Danesh-Meyer","year":"2005","unstructured":"Danesh-Meyer H, Savino PJ, Gamble GG (2005) Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 112:1098\u20131103","journal-title":"Ophthalmology"},{"key":"1616_CR8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jama.287.1.92","volume":"287","author":"GW Smetana","year":"2002","unstructured":"Smetana GW, Shmerling RH (2002) Does this patient have temporal arteritis? JAMA 287:92\u2013101","journal-title":"JAMA"},{"key":"1616_CR9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","volume":"83","author":"G Nesher","year":"2004","unstructured":"Nesher G, Berkun Y, Mates M et al (2004) Risk factors for cranial ischemic complications in giant cell arteritis. Med Baltim 83:114\u2013122","journal-title":"Med Baltim"},{"key":"1616_CR10","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group","year":"1995","unstructured":"The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581\u20131587","journal-title":"N Engl J Med"},{"key":"1616_CR11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","volume":"359","author":"W Hacke","year":"2008","unstructured":"Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317\u20131329","journal-title":"N Engl J Med"},{"key":"1616_CR12","first-page":"S62","volume":"25","author":"B Dasgupta","year":"2007","unstructured":"Dasgupta B, Hassan N, British Society for Rheumatology Guidelines Group (2007) Giant cell arteritis: recent advances and guidelines for management. Clin Exp Rheumatol 25:S62\u2013S65","journal-title":"Clin Exp Rheumatol"},{"key":"1616_CR13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7861\/clinmedicine.10-4-381","volume":"10","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta B, Giant Cell Arteritis Guideline Development Group (2010) Concise guidance: diagnosis and management of giant cell arteritis. Clin Med 10:381\u2013386","journal-title":"Clin Med"},{"key":"1616_CR14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310\u2013317","journal-title":"Ann Rheum Dis"},{"key":"1616_CR15","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122\u20131128","journal-title":"Arthritis Rheum"},{"key":"1616_CR16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","volume":"41","author":"MC Cid","year":"1998","unstructured":"Cid MC, Font C, Oristrell J et al (1998) Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41:26\u201332","journal-title":"Arthritis Rheum"},{"key":"1616_CR17","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","volume":"107","author":"J Hernandez-Rodriguez","year":"2003","unstructured":"Hernandez-Rodriguez J, Segarra M, Vilardell C et al (2003) Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107:2428\u20132434","journal-title":"Circulation"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1616-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1616-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:51:46Z","timestamp":1559119906000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1616-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,18]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["1616"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1616-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,18]]}}}